YM155 (Sepantronium Bromide)

For research use only.

Catalog No.S1130

144 publications

YM155 (Sepantronium Bromide) Chemical Structure

CAS No. 781661-94-7

YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.

Selleck's YM155 (Sepantronium Bromide) has been cited by 144 publications

Purity & Quality Control

Choose Selective Survivin Inhibitors

Biological Activity

Description YM155 (Sepantronium Bromide) is a potent survivin suppressant by inhibiting Survivin promoter activity with IC50 of 0.54 nM in HeLa-SURP-luc and CHO-SV40-luc cells; does not significantly inhibit SV40 promoter activity, but is observed to slightly inhibit the interaction of Survivin with XIAP. YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells. Phase 2.
Targets
Survivin [1]
(HeLa-SURP-luc, CHO-SV40-luc cells)
0.54 nM
In vitro

YM155 is not sensitive to survivn gene promoter-driven luciferase reporter activity even at 30 μM. YM155 significantly inhibits endogenous survivin expression in PC-3 and PPC-1 human HRPC cells with deficient p53 through transcriptional inhibition of the survivin gene promoter. On the contrary YM155 shows no sufficient effect on protein expression of c-IAP2, XIAP, Bcl-2, Bcl-xL, Bad, α-actin, and β-tubulin at 100 nM. YM155 indicates great apoptosis in human cancer cell lines including PC-3 and PPC-1 with a concomitant increase in caspase-3 activity. YM155 potently inhibits human cancer cell lines (mutated or truncated p53) including PC-3, PPC-1, DU145, TSU-Pr1, 22Rv1, SK-MEL-5 and A375 with IC50 from 2.3 to 11 nM, respectively. [1] YM155 increases the sensitivity of NSCLC cells to γ-radiation. The combination of YM155 and γ-radiation increases both the number of apoptotic cells and the activity of caspase-3. YM155 delays the repair of radiation-induced double-strand breaks in nuclear DNA. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kasumi-1 NYfxTYFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXUOXQ4OiCq NYjXPFUyTE2VTx?= NH3mVZBKSzVyPUCuNFA6KMLzIECuNFAxQSEQvF2= NEjZN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
M-07e NHPrZZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfORXI4OiCq MVLEUXNQ M{TCdWlEPTB;MD6wOFAhyrFiMD6wNVMh|ryP NHzDNoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
THP-1 NXnD[ZZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fO[lczKGh? MVXEUXNQ MoLMTWM2OD1yLkC1NUDDuSByLkCxN{DPxE1? NGLCcXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
CMK MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fRVFczKGh? MkT2SG1UVw>? M2riWGlEPTB;MD6wOVMhyrFiMD6wNFkh|ryP M4DzWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
MV4-11 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzyNoN3PzJiaB?= NF3TflhFVVOR NVrKOo9GUUN3ME2wMlA2PSEEsTCwMlAzQCEQvF2= NHv0SZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
AML-193 M4jjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX36epk6PzJiaB?= MmexSG1UVw>? MmLVTWM2OD1yLkS2NkDDuSByLkC2NEDPxE1? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
HL-60 MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:3NkBp NHXmZW1FVVOR NELNXHJKSzVyPUCuNFAyKMLzIECuNFAxOiEQvF2= NG\FWno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
ML-2 M2DFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;aO|IhcA>? NV3ZSVJSTE2VTx?= M{\lSmlEPTB;MD6wNFkhyrFiMD6wNFIh|ryP NF;KUG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
OCI/AML3 M1HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3js[lczKGh? M2rTNmROW09? MlnMTWM2OD1yLkCxNUDDuSByLkCwNkDPxE1? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
HEL M2fYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLIW|BrPzJiaB?= NVL1c4FwTE2VTx?= M33UdmlEPTB;MD61OVkhyrFiMD6wN|gh|ryP NVKxW21kRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OVk4OzFpPkK1OlU6PzNzPD;hQi=>
ME-1 NVfPeIJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3y1eVczKGh? NF20U25FVVOR Mn;BTWM2OD1yLk[4OEDDuSByLkG3PUDPxE1? MlHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NUm3N|EoRjJ3NkW5O|MyRC:jPh?=
THP-1 NWXSRYpNSXCxcITvd4l{KEG|c3H5 MY[xxsDPxE1? M{jNdVczKGh? MmDESG1UVw>? Ml\QbY5lfWOnczDhdI9xfG:|aYO= M1vWSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
M-07e MorWSpVv[3Srb36gRZN{[Xl? NV\ieXJxOOLCk{JCpO69VQ>? NYHSdoF5PzJiaB?= NVvYO2hsTE2VTx?= NVPPSFR4cW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
THP-1 MlzlSpVv[3Srb36gRZN{[Xl? M2mxflDjiJNzwrFOwG0> MVe3NkBp NFLkZ4dFVVOR M{exT4lv\HWlZYOg[I94dnKnZ4XsZZRqd25ib3[gV5Vzfmm4aX6= NGf6Rpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
CMK NWrKNFNETnWwY4Tpc44hSXO|YYm= M{nJTFDjiJNzwrFOwG0> NUPXS5UyPzJiaB?= MULEUXNQ MXnpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw M1TWclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
AML-193 Mln6SpVv[3Srb36gRZN{[Xl? MXuw5qCUOcLizszN M1;oeFczKGh? M1HHdmROW09? MnnkbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDTeZJ3cX[rbh?= NInON289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[1PVc{OSd-MkW2OVk4OzF:L3G+
Kasumi-1 M3PHW2Z2dmO2aX;uJGF{e2G7 NID6VFgx6oDVMdMg{txO NW[2cYV1PzJiaB?= M1S4UWROW09? MWXpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGP1dpZqfmmw MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ3OUezNUc,OjV4NUm3N|E9N2F-
MV4-11 NHzN[5RHfW6ldHnvckBCe3OjeR?= M320ZlDjiJNzwrFOwG0> MlLLO|IhcA>? MljwSG1UVw>? NWH5NYRwcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBUfXK4aY\pci=> M4Hhe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkW5O|MyLz5{NU[1PVc{OTxxYU6=
MUG-Chor  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjDflN[OC13IN88US=> NInz[48zPC92ODDo M4DoTGlEPTB;Nz6wOgKBkW6PIH\vdkA1QGh? MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4NECxPFUoRjJ3NkSwNVg2RC:jPh?=
U-CH1  MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTxUVVJOC13IN88US=> Mm\aNlQwPDhiaB?= M2H0RWlEPTB;OT6wN-KBkW6PIH\vdkA1QGh? NXz5dXNURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2OFAyQDVpPkK1OlQxOTh3PD;hQi=>
KATOIII MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rh[|ExNzJyIH7N NF;GOYM1QCCq NVHWNHd{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MkfVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{WwOVUoRjJ3NkO1NFU2RC:jPh?=
AGS  NXvHUnJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvrfZRTOTBxMkCgcm0> NInwU3A1QCCq MkjwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4M{WwOVUoRjJ3NkO1NFU2RC:jPh?=
SACC-83 MmT4SpVv[3Srb36gRZN{[Xl? NFTqbmE2KG6P MVu0PEBp NWTXTIYz\GWlcnXhd4V{KG63Y3zlZZIh\XiycnXzd4lwdiCxZjDITWYuOc7z MoPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2OEW2N|UoRjJ3NEi1OlM2RC:jPh?=
INA-6 NH3xbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzjUGQxNTVyMDDuUS=> NHfBWXQ1QCCq NXT2UZV4cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIjIfpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
U-266 Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4e2RlAuPTByIH7N Mki3OFghcA>? NXK4dZlCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4HaPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
MOLP-8 M4XiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0SmgxNTVyMDDuUS=> M2riWlQ5KGh? MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnLrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
HG-1 NHy0ZWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nlcFAuPTByIH7N NXXGTZNGPDhiaB?= NH;6c|RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NVi1NlhDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
NCI-H929 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfCNE02ODBibl2= NE\tWG41QCCq MlPNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYn3flU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
OPM-2 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe5dplUOC13MECgcm0> NEDTTXA1QCCq NE[3SHZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4K4OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Mkm2PVc5Lz5{NUK5Olk4QDxxYU6=
L-363 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWP4S5ZMOC13MECgcm0> MVi0PEBp MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
MOLP-2 NHHIVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHWxVpgxNTVyMDDuUS=> MUC0PEBp NHy4S5FqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTJ7Nkm3PEc,OjV{OU[5O|g9N2F-
KMS-12-BM NFPtZ3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkL1NE02ODBibl2= NUXvNG45PDhiaB?= NYjheVJRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NH;Idm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5Olk4QCd-MkWyPVY6Pzh:L3G+
SK-MM-2 NXPYOpZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTuVYN1OC13MECgcm0> MXK0PEBp NH;oVohqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWTUZW5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
U-266 NFfMe4VCeG:ydH;zbZMhSXO|YYm= NFH6U|MxNTVyIH7N NFj4T|UzPCCq NWTkcXJjcW6mdXPld{BieG:ydH;zbZM> NUn1[YVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVY6PzhpPkK1Nlk3QTd6PD;hQi=>
INA-6  M3K2O2Fxd3C2b4Ppd{BCe3OjeR?= MWCwMVUxKG6P NVXoZWpCOjRiaB?= NF7CcFFqdmS3Y3XzJIFxd3C2b4Ppdy=> MmXBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OU[5O|goRjJ3Mkm2PVc5RC:jPh?=
MCF7 M{LZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG3NkBp MoLxTWM2OD1zMzFCtUA3KG6P NEX0bXQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamR6 MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjnOGM4OiCq MVTJR|UxRThiwsGgOkBvVQ>? NF35fo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MCF7-TamR7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjDVpE4OiCq NEPiSXRKSzVyPUigxtEhOyCwTR?= M2\ud|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKwNlI2Lz5{NUKyNFIzPTxxYU6=
MCF7-TamR8 M2G4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXOO|IhcA>? NIXCUHNKSzVyPUG1JOKyKDZibl2= NYTNbVh5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamC3 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnl[2w4OiCq MVnJR|UxRTZiwsGgN{BvVQ>? NYTFWnpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
MCF7-TamC6 NH74fnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X2O|czKGh? M1XFSmlEPTB;NjFCtUAxNjFibl2= NHLUdHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUKyNFIzPSd-MkWyNlAzOjV:L3G+
MDA-MB-231 NXrzUnZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TyWVczKGh? MWrJR|UxRTViwsGgNUBvVQ>? MlTCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{MkCyNlUoRjJ3MkKwNlI2RC:jPh?=
SK-BR-3 Ml7mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ob|czKGh? MXPJR|UxRTdiwsGgNE4{KG6P NVzoe3lIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlAzOjVpPkK1NlIxOjJ3PD;hQi=>
Eca109 NFL6RZNHfW6ldHnvckBCe3OjeR?= MXmxMVUxKG6P M3\odVQ5KGh? MXvEUXNQ MoK4d5VxeHKnc4Pld{B{fXK4aY\pckBmgHC{ZYPzbY9vKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MljzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzM{mzPVUoRjJ3MUO5N|k2RC:jPh?=
TE13 MmTESpVv[3Srb36gRZN{[Xl? NGnXNYoyNTVyIH7N M{L5dVQ5KGh? NGj4U2ZFVVOR NHHrR4N{fXCycnXzd4V{KHO3co\peolvKGW6cILld5Nqd25iaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1vYNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUO5N|k2Lz5{NUGzPVM6PTxxYU6=
Eca109 NHS5dXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXPVmwxNTFyMDDuUS=> M1HFOFI1NzR6IHi= M{S2[2ROW09? MUHk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF|OUO5OUc,OjVzM{mzPVU9N2F-
TE13 NVPXdYFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4i3eFAuOTByIH7N NF:4OZUzPC92ODDo NUXOSHFITE2VTx?= MWnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NU[xT2JORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxN|k{QTVpPkK1NVM6Ozl3PD;hQi=>
MT-3 NILhWFZMcW6jc3WgRZN{[Xl? NHrDcVk4OiCq NHPpTVRFVVOR Mnj6TWM2OD1{Lki2JOKyKDBwNUSgcm0h\m:{IFTSOEBmgHC{ZYPzbY9v NYrHZoZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4OlY2QDVpPkK0PFY3PTh3PD;hQi=>
MDA-MB-468 M2n2eWtqdmG|ZTDBd5NigQ>? NYL2fGxiPzJiaB?= MWPEUXNQ NW\UdYVEUUN3ME2wMlEyKMLzIECuNFEhdk1iZn;yJGRTPCCneIDy[ZN{cW:w MonYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
SUM-159 MV;LbY5ie2ViQYPzZZk> NF7IXGY4OiCq NFL2NVFFVVOR M4nwb2lEPTB;MT63NkDDuSByLkOzJI5OKG[xcjDEVlQh\XiycnXzd4lwdg>? MorKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
MT-3 NFK2cm5McW6jc3WgRZN{[Xl? NITzeJU4OiCq M1XTTmROW09? NGCycJZKSzVyPUW0MlEyKMLzIESuN|Ihdk1iZn;yJGRTPSCneIDy[ZN{cW:w MkTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6Nk[1PFUoRjJ2OE[2OVg2RC:jPh?=
MDA-MB-468 MoP1T4lv[XOnIFHzd4F6 NUn4V3BpPzJiaB?= M{flOWROW09? Mnm3TWM2OD1yLkC3JOKyKDBwMEKgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v M4ewc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OE[2OVg2Lz5{NEi2OlU5PTxxYU6=
SUM-159 M4HaSmtqdmG|ZTDBd5NigQ>? M2G2b|czKGh? NXL1XnIzTE2VTx?= MoT0TWM2OD14OT60JOKyKDRwMkOgcm0h\m:{IFTSOUBmgHC{ZYPzbY9v NGfyfG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
MT-3 + NAC MWLLbY5ie2ViQYPzZZk> NUPMUlVCPzJiaB?= M2\FdWROW09? M{W2b2lEPTB;NU[uNkDDuSB{LkC3JI5OKG[xcjDEVlUh\XiycnXzd4lwdg>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh4NkW4OUc,OjR6Nk[1PFU9N2F-
MT-3 + SB203580 MVvLbY5ie2ViQYPzZZk> M1PSSVczKGh? M{DBfmROW09? M1K1NGlEPTB;M{iuOFEhyrFiNT6wNkBvVSCob4KgSHI2KGW6cILld5Nqd25? NG\qSYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi2OlU5PSd-MkS4OlY2QDV:L3G+
DB NHfrOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DQNFExKG6P M3vBWlI1KGh? NF65fHlFVVOR Mmj1bY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M2H3ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi2OVk2Lz5{NES4OlU6PTxxYU6=
SU-DHL-8 NVK2SJMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNEBvVQ>? MkDZNlQhcA>? MlX5SG1UVw>? NFq0WmlqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NkW5OUc,OjR2OE[1PVU9N2F-
WSU-DLCL2 M3\YcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;PVowyOCCwTR?= M13a[VI1KGh? NUS3Voh6TE2VTx?= MoLibY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;u M{W5cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEi2OVk2Lz5{NES4OlU6PTxxYU6=
ACC-2 NXThR4FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ueIExNTFyMDDuUS=> MkfGNlQhcA>? MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5MEm5OUc,OjR|N{C5PVU9N2F-
ACC-2 M33teWFxd3C2b4Ppd{BCe3OjeR?= MYqwMVIxKG6P NWjOR2pJOjRiaB?= MVPpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDN5MEm5OUc,OjR|N{C5PVU9N2F-
ACC-2 MWTGeY5kfGmxbjDBd5NigQ>? M13D[VAuOjBibl2= NXi0ZYlDOjRiaB?= MVzpcoNz\WG|ZYOgeIhmKGOxbo\ldpNqd25ib3[gUGM{USC2bzDMR|NKUQ>? M334UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2M{ewPVk2Lz5{NEO3NFk6PTxxYU6=
BFTC905 NIfEe25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HMeVAuOTByMDDuUS=> MmD2OFghcMLi NEXJUVVFVVOR M4HkRmlEPTB;MkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7N{[0OEc,OjR{OUe2OFQ9N2F-
T24 NVL5WW9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq3XHoxNTFyMECgcm0> M{i2bFQ5KGkEoB?= MYnEUXNQ MUTJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
TSGH8301  Mon5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;VNE0yODByIH7N M{HyS|Q5KGkEoB?= NYCzZmo6TE2VTx?= MYPJR|UxRTJyIH7NMEBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NEjZdJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
BFTC909 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGSxe3YxNTFyMECgcm0> MY[0PEBpyqB? MXvEUXNQ NYroPHVwUUN3ME2yNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnvhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUe2OFQoRjJ2Mkm3OlQ1RC:jPh?=
BFTC905 MmrrRZBweHSxc3nzJGF{e2G7 NEjHXZIzOCCwTR?= NI\5PI81QCCq NH\1NXRFVVOR MlPqbY5lfWOnczDhdI9xfG:|aYO= NEGzW5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
BFTC905 NFW3XZpHfW6ldHnvckBCe3OjeR?= NYTrXGxFOjBibl2= MnjvOFghcA>? M2LVSmROW09? NV22eHR7\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKEyFM1KtTWk> NFnQS|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5O|Y1PCd-MkSyPVc3PDR:L3G+
A2780p M{n2dWZ2dmO2aX;uJGF{e2G7 M37EVFAuOTByIH7N NXjRSJV[OjRiaB?= MVHEUXNQ MUPpcoR2[2W|IGP1dpZqfmmwIHTve45z\We3bHH0bY9vyqB? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
A2780cis MlzVSpVv[3Srb36gRZN{[Xl? NUHXZotoOC1zMECgcm0> NVe0VYZVOjRiaB?= MnT6SG1UVw>? M2P1T4lv\HWlZYOgV5Vzfmm4aX6g[I94dnKnZ4XsZZRqd28EoB?= MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ4Mki3OUc,OjR{NkK4O|U9N2F-
A2780p M2j2[2Fxd3C2b4Ppd{BCe3OjeR?= MXS1MVExOCCwTR?= MkXiNlQwPDhiaB?= MmixSG1UVw>? M2n5d4lv[3KnYYPld{BieG:ydH;zbZMhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NW\UOok3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlI5PzVpPkK0NlYzQDd3PD;hQi=>
A2780cis M3XtRWFxd3C2b4Ppd{BCe3OjeR?= MoO4OU0yODBibl2= MUWyOE81QCCq M2S3emROW09? MWrpcoNz\WG|ZYOgZZBweHSxc3nzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NVjuOXVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyOlI5PzVpPkK0NlYzQDd3PD;hQi=>
SH-SY5Y MYjBdI9xfG:|aYOgRZN{[Xl? NFe1[YYyNzFyL{GwNEDDvU1? M{T6eVczKGh? NGrFUWRFVVOR NH7xbpVqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1vpRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkW0OVYxLz5{NEK1OFU3ODxxYU6=
HL-60 NFO5RYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;iO|LDqGh? M4rmeWROW09? NEix[25KSzVyPUCuN{BvVQ>? Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ|NkG4PFYzRC:jPh?=
U937  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLpO|LDqGh? MVnEUXNQ MmLkTWM2OD1yLkigcm0> NXLm[YdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVg5PjJpPkKzOlE5QDZ{PD;hQi=>
HL-60  MYPGeY5kfGmxbjDBd5NigQ>? NVHOSY1COcLizszN MXm2M|EzNzJ2IHi= NVHleJp[TE2VTx?= NYO0dJpQcW6qaXLpeJMhfGinIHX4dJJme3Orb36gc4Yhe3W{dnn2bY4> MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzOEi2Nkc,OjN4MUi4OlI9N2F-
U937  Ml2wSpVv[3Srb36gRZN{[Xl? MoDYNeKh|ryP M3nsfVYwOTJxMkSgbC=> Mn7uSG1UVw>? MWLpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDzeZJ3cX[rbh?= MkfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUi4OlIoRjJ|NkG4PFYzRC:jPh?=
HL-60 M3mwOGFxd3C2b4Ppd{BCe3OjeR?= NFqxUooxNjFxMTFOwG0> NUPQZZZVQCCq NIjUTXpFVVOR Mkn1bY5lfWOnczDhdI9xfG:|aYO= NHXUfIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xPFg3Oid-MkO2NVg5PjJ:L3G+
Sk-NEP-1  MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxMVExODByIH7N NEfCcVczPCCq NUnwUYVVTE2VTx?= MWfJR|UxRTFyMDDuUS=> MnvtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nke2PVkoRjJ|Mk[3Olk6RC:jPh?=
SK-NEP-1  MXjBdI9xfG:|aYOgRZN{[Xl? NWm3U21oPTBxMUCwJI5O NITKOmEyOi9{NDDo NVnDWHFQTE2VTx?= NGq1[2pqdmS3Y3XzJIFxd3C2b4Ppdy=> Mn;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{Nke2PVkoRjJ|Mk[3Olk6RC:jPh?=
TC-32 NVHuXoJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\4OWYxNjFvMUCwNEBvVQ>? MkjzSWM2OD1|LkCgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M2jZd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
TC-71 NYjj[WZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\6NE4yNTFyMECgcm0> M3TXfGVEPTB;NT63JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MmrwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
SK-ES-1 M1;ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X5XFAvOS1zMECwJI5O M3i3ZWVEPTB;Mj64JI5ONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl4MUe2N{c,OjJ7NkG3OlM9N2F-
RD-ES MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHez[GQxNjFvMUCwNEBvVQ>? MmDISWM2OD14LkKgcm0tKGmwaHnibZR{KGOnbHyg[5Jwf3SqIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1PkPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OU[xO|Y{Lz5{Mkm2NVc3OzxxYU6=
HEK293 M4DXPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW2TG1xOC5zLUGwNFAhdk1? M2izNGVEPTB;MkOuNEBvVSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Mn3qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NkG3OlMoRjJ{OU[xO|Y{RC:jPh?=
M059J M17rdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTnSmExNTVyIH7N NUHhU|hxPDhiaB?= NH\hNJNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGm0eI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059K MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDDdmMxNTVyIH7N NHP5TZQ1QCCq M{fvUYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd5MEGxNEc,OjJ5N{CxNVA9N2F-
M059J MYjBdI9xfG:|aYOgRZN{[Xl? NYnCeWRYOzBibl2= M2LNbVI1KGh? NYPme4N5cW6mdXPld{BieG:ydH;zbZM> NHqyOGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mke3NFEyOCd-MkK3O|AyOTB:L3G+
M059K MnHaRZBweHSxc3nzJGF{e2G7 MXSzNEBvVQ>? NH\Yeo4zPCCq MYjpcoR2[2W|IHHwc5B1d3Orcx?= M1LaeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{ewNVExLz5{Mke3NFEyODxxYU6=
PANC-1 NX\MT3hMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPuNE4xOS1zMECwJI5O M4j2WlQ5KGh? M2[4fmlEPTB;Mz62PUBvVQ>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O|E9N2F-
MIAPaCa-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLIbnEyOC5yMT2xNFAxKG6P Mn3kOFghcA>? NWDkUYRHUUN3ME2yPU4{PiCwTR?= M{nJSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{KzPFcyLz5{MkeyN|g4OTxxYU6=
BxPC-3 M3z6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf0NE4xOS1zMECwJI5O M{H2bFQ5KGh? NYr2[5hOUUN3ME2zNE4zPiCwTR?= NYj5TGRURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
PANC-1 MonXSpVv[3Srb36gRZN{[Xl? MV[wMVExODBibl2= MUGyOEBp MmrZbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDYTWFRKGGwZDDzeZJ3cX[rbjDlfJBz\XO|aX;u MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd{M{i3NUc,OjJ5MkO4O|E9N2F-
MIAPaCa-2 NVvYTIVFTnWwY4Tpc44hSXO|YYm= MX:wMVExODBibl2= NIK3SpMzPCCq MYfpcoR2[2W|IHTve45z\We3bHH0bY9vKG:oIGjJRXAh[W6mIIP1dpZqfmmwIHX4dJJme3Orb36= NELsdHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkeyN|g4OSd-MkK3NlM5PzF:L3G+
BxPC-3 NXHaN4x2TnWwY4Tpc44hSXO|YYm= MX2wMVExODBibl2= Ml[2NlQhcA>? NGnUVGtqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJHhKSVBiYX7kJJN2en[rdnnuJIV5eHKnc4Ppc44> NWHxVWQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3NlM5PzFpPkKyO|I{QDdzPD;hQi=>
RPMI-7951 NHLwXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPqS2k2OD1|LkKgcm0> MmLZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{e1NFIoRjJzN{O3OVAzRC:jPh?=
SK-MEL-5 Mn\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjHTVUxRTRwMjDuUS=> MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
A375 NH7N[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfINZRHT0l3ME22MlMhdk1? M{XpZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{O3OVAzLz5{MUezO|UxOjxxYU6=
SK-MEL-28 NEnxRo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnneVNqT0l3ME23MlYhdk1? MoK0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5M{e1NFIoRjJzN{O3OVAzRC:jPh?=
SK-MEL-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHHTVUxRTFzIH7N MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd|N{WwNkc,OjF5M{e1NFI9N2F-
DB NF\UbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWS0POKhcA>? NX;NcYo1T0l3ME2zMlUhdk1? MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ|N{WwPEc,OjF{M{e1NFg9N2F-
Pfeiffer M{TEUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjCV4w1QMLiaB?= NEfKUHdIUTVyPUOuPUBvVQ>? NImwUpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUKzO|UxQCd-MkGyN|c2ODh:L3G+
SU-DHL-5 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi0POKhcA>? MnXOS2k2OD1yLkKzJI5O MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ|N{WwPEc,OjF{M{e1NFg9N2F-
SU-DHL-8 NUPNTZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[xWI1sPDkEoHi= Mn75S2k2OD1zLkSgcm0> MlqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{M{e1NFgoRjJzMkO3OVA5RC:jPh?=
WSU-DLCL-2 NH3SSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK0POKhcA>? NHPVOZBIUTVyPUGuOEBvVQ>? MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTJ|N{WwPEc,OjF{M{e1NFg9N2F-
A549 NVjFe5ppT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYHHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDBOVQ6KGOnbHzzMEBKSzVyPUCuNFE{PM7:TR?= MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDhzNEO3OEc,Ojh6MUSzO|Q9N2F-
DU145 M3PqVmN6fG:2b4jpZ4l1gSCjc4PhfS=> NFLp[YtEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFXTF2NTDj[YxteyCkeTDNWHQh[XO|YYmsJGVEPTB;MD6wNVM5|ryP NWjVOpIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
PC3 MY\DfZRwfG:6aXPpeJkh[XO|YYm= NX3wV|JJS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGK7IF3UWEBie3OjeTygSWM2OD1yLkC5Nu69VQ>? NV3ZSZBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3O|Q1OjZpPkK4O|c1PDJ4PD;hQi=>
A549 Mn3QSpVv[3Srb36gZZN{[Xl? MmjWTY5pcWKrdHnvckBw\iCSQVuxJIlvKGi3bXHuJGE2PDliY3XscJMtKEmFNUC9NE42|ryP M2r0XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEG0N|c1Lz5{OEixOFM4PDxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / XIAP / Caspase-7 / Caspase-9 / Caspase-3 / Cleaved Caspase-8 / PARP; 

PubMed: 26771139     


YM155 treatment decreased survivin expression without affecting XIAP and induced cleavage of caspases. Protein expression (caspase-3, -7, -9, -8, PARP) was detected by Western Blot analysis. 

β-catenin / c-Myc / Cyclin D1 / CD44 ; 

PubMed: 26771139     


YM155 inhibited expression of CSC molecules. SGC-7901 cells were treated with YM155 at indicated doses for 24 hours. The protein levels of genes were determined by Western Blot.

p-STAT3 / STAT3 ; 

PubMed: 22723871     


Levels of phosphorylated STAT3 and expression of survivin were analyzed by Western blotting after a 24-hours treatment with YM155 and 48 hours after transfection of 40 nM siRNA.

26771139 22723871
Immunofluorescence
EGFR; 

PubMed: 22723871     


YM155 (10 nM) induced the nuclear EGFR accumulation. PANC-1 cells were stained with anti-EGFR, anti-Alexa Fluor 488, and DAPI after the YM155 treatment. Scale bars: 10 µm.

PARP-1 / PAR ; 

PubMed: 26090615     


A. Nuclear accumulation of active PARP-1 in KYSE410 cells after 12 h of YM155 treatment was evaluated using immunofluorescent analysis. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. C. Accumulation of the poly-ADP polymer in KYSE410 was evaluated using immunofluorescent analysis after YM155 treatment for 12 h. Nuclei were stained with DAPI, as shown in blue. Scale bars: 10 μm. 

22723871 26090615
Growth inhibition assay
Cell viability; 

PubMed: 29636860     


Cells were grown in 96-well plates for 24 h and treated with the indicated concentrations of YM155 or docetaxel for 72 h, and cell survival was determined by MTT assay.

29636860
In vivo YM155 completely inhibits the tumor growth of PC-3 s.c. xenografted prostate tumors at doses of 3 and 10 mg/kg, without body weight loss and blood cell count decrease. Pharmacokinetic analysis shows that YM155 is highly distributed to tumor tissue. Moreover, YM155 shows 80% TGI at a dose of 5 mg/kg in PC-3 orthotopic xenografts. [1] The combination therapy with YM155 and γ-radiation shows great antitumor activity against H460 or Calu6 xenografts in nude mice. [2]

Protocol

Kinase Assay:

[1]

- Collapse

Promoter-luciferase reporter assay:

A 2,767-bp sequence of human survivin gene promoter is isolated from human genomic DNA by PCR using Pyrobest polymerase and the following primers: 5
Cell Research:

[1]

- Collapse
  • Cell lines: Hormone refractory prostate cancer cell lines (PC-3, PPC-1, DU145, TSU-Pr1 and 22Rv1) and malignant melanoma cell lines (SK-MEL-5 and A375)
  • Concentrations: ~ 100 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded in 96-well plates at a density of 5-40 × 103. YM155 is dissolved in DMSO and added to cells for 48 hours. Then the cell count is determined by sulforhodamine B assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: PC-3 s.c. (orthotopic) xenografts in male nude mice (BALB/c nu/nu)
  • Dosages: 5 mg/kg
  • Administration: Subcutaneous injection as a 3-day continuous infusion per week for 3 weeks by an implanted micro-osmotic pump
    (Only for Reference)

Solubility (25°C)

In vitro Water 89 mg/mL (200.77 mM)
DMSO 55 mg/mL (124.07 mM)
Ethanol 6 mg/mL (13.53 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 443.29
Formula

C20H19BrN4O3

CAS No. 781661-94-7
Storage powder
in solvent
Synonyms N/A
Smiles CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01023386 Completed Drug: YM155 Cancer Astellas Pharma Inc November 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Survivin Signaling Pathway Map

Related Survivin Products

Tags: buy YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) supplier | purchase YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) cost | YM155 (Sepantronium Bromide) manufacturer | order YM155 (Sepantronium Bromide) | YM155 (Sepantronium Bromide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID